Imicore 500mg Injection is a combination antibiotic formulation containing Imipenem 500mg and Cilastatin 500mg, indicated for the treatment of serious bacterial infections caused by susceptible strains of both Gram-positive and Gram-negative organisms. Imipenem, a broad-spectrum carbapenem antibiotic, exerts bactericidal activity by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Cilastatin is a renal dehydropeptidase inhibitor that prevents the enzymatic degradation of Imipenem in the kidneys, thereby enhancing its therapeutic efficacy and prolonging its half-life. Imicore is primarily utilized in the management of complicated intra-abdominal infections, urinary tract infections, respiratory tract infections, septicemia, and skin and soft tissue infections. The injection is administered intravenously, with dosage adjusted according to the severity of infection, renal function, and patient-specific factors. Adverse effects may include hypersensitivity reactions, gastrointestinal disturbances, and potential nephrotoxicity, necessitating careful monitoring during therapy. Imicore should be used with caution in patients with a history of seizures or renal impairment. This combination offers a potent option against multidrug-resistant pathogens, making it a valuable agent in hospital settings where resistant infections are prevalent. Proper aseptic technique and adherence to recommended dosing schedules are essential to optimize clinical outcomes.